IN MPJE cheat sheet

Minnesota licenses pharmacists, registers pharmacy technicians, and registers interns through the Board of Pharmacy; all three credentials must be current and in good standing before practicing in the state.

A Minnesota pharmacist license requires graduation from an ACPE-accredited program, passage of NAPLEX and MPJE, and a jurisprudence requirement; licensure by reciprocity/score transfer goes through the Board, not NABP alone.

Pharmacy technicians in Minnesota are registered (not licensed) by the Board; registration requires application, fee, and compliance with Board rules, and technician registration is distinct from national PTCB certification.

Pharmacy interns must be enrolled in an accredited pharmacy program and registered with the Board; intern registration permits supervised practice toward licensure and expires per Board rule.

A pharmacy must obtain a Board-issued pharmacy license for each location before dispensing; the license identifies the pharmacist-in-charge (PIC) and the licensed premises.

Out-of-state pharmacists generally may not practice into Minnesota on another state's license; nonresident pharmacies dispensing to Minnesota patients must register with the Minnesota Board as a nonresident pharmacy.

Credential renewals are time-limited; practicing on an expired license, registration, or pharmacy license is grounds for discipline even if renewal is later completed.

Change-of-address, name, employment, or PIC changes must be reported to the Board within the timeframe set by rule; failure to report is an independent violation.

Federal CSA places drugs in Schedules I–V; Schedule II has the strictest controls, no refills, and requires a written or qualifying electronic prescription except in defined emergencies.

Minnesota adopts the federal schedules by reference and adds state-specific controls; Minnesota Schedule I includes drugs with no accepted medical use and high abuse potential.

Minnesota's prescription monitoring program (PMP) requires dispensers to report controlled substance dispensations to the state database; pharmacists must check the PMP in specified circumstances before dispensing controlled substances.

Schedule II prescriptions may not be refilled; Schedule III–IV may be refilled up to five times within six months of issue; Schedule V refills follow state and label limits.

Controlled substance records (inventory, dispensing, invoices) must be kept per federal and state retention rules; Minnesota generally requires prescription records be retained for at least two years.

A DEA registration is required for each principal place of business where controlled substances are handled; state licensure is a prerequisite to DEA registration in Minnesota.

Theft or significant loss of controlled substances must be reported to DEA and to the Minnesota Board; the report is separate from routine inventory reconciliation.

Minnesota law restricts prescribing and dispensing of certain controlled substances and requires specific documentation for opioid prescriptions, including PDMP review and patient risk assessment.

A valid prescription requires the patient's name and address, drug name/strength/quantity, directions, prescriber's name and DEA number (for controlled substances), and date of issue.

Minnesota requires that prescriptions be dispensed as written unless substitution is permitted; generic substitution is allowed only when the prescriber has not prohibited it and the substituted product is therapeutically equivalent.

A pharmacist may not dispense on an expired prescription or one lacking required elements; the pharmacist must verify questionable prescriptions with the prescriber and document the contact.

Refills must be authorized by the prescriber and must not exceed the number stated or the legal maximum; Schedule II cannot be refilled.

Prescription transfers between pharmacies must be documented, include all required information, and are subject to limits for controlled substances under federal and state rules.

E-prescribing of controlled substances requires DEA-compliant software; paper prescriptions remain valid where allowed, but forgery indicators and prescriber verification are required.

Labels must include pharmacy name and address, prescription number, date, patient name, directions, drug name/strength, quantity, prescriber, and required auxiliary and cautionary statements.

Patient counseling must be offered on new prescriptions and when the pharmacist deems necessary; refusal must be documented, and counseling must be provided in a manner the patient understands.

Drugs must be stored under conditions that ensure stability; temperature, light, and humidity controls must be monitored and documented, and expired or adulterated stock must be quarantined.

Controlled substance inventory must be taken at registration and biennially thereafter; the inventory must be exact for Schedule II and estimated for III–V, and records retained.

Returns and reverse distribution must be documented; controlled substances may not be returned to stock after dispensing, and returned drugs must be handled under DEA and Board rules.

Drug recalls require identification of affected lots, quarantine, notification of patients when necessary, and documentation of the recall response.

Theft or loss of controlled substances must be reported to DEA (Form 106) and to the Minnesota Board; significant losses also require review of security controls.

Automated dispensing systems must maintain audit trails, restrict access, and be subject to the same recordkeeping and security standards as manual systems.

Records must be readily retrievable and retained for the required period; prescription and controlled substance records must be available for Board and DEA inspection.

Security requires limited access to the pharmacy, locked storage of controlled substances, and documented key/alarm control; the PIC is responsible for overall security.

Pharmacists may perform patient assessment, drug therapy review, and medication management; collaborative practice agreements allow defined therapy changes under protocol.

Minnesota pharmacists may administer immunizations to patients meeting age and protocol requirements; documentation and reporting to the state immunization registry are required.

Pharmacists may dispense naloxone under a standing order or protocol; no separate prescriber order is required when the state standing order is used.

Technicians may perform duties delegated by the supervising pharmacist, including preparation and dispensing tasks, but may not perform clinical assessment or final verification.

The pharmacist-in-charge is responsible for supervision, training, and ensuring technicians work within their registered scope; ratio and supervision rules must be followed.

Interns may perform pharmacist tasks under direct supervision of a licensed pharmacist; the supervising pharmacist remains responsible for the intern's actions.

A pharmacist may not delegate final verification of a prescription or clinical judgment to a technician; the pharmacist must review the completed prescription before dispensing.

Delegation must be documented and consistent with Board rules; a pharmacist who permits an unregistered or unsupervised person to perform restricted acts is subject to discipline.

Medication errors must be documented and reviewed; serious errors and sentinel events require internal review and may require reporting to the Board or other authorities.

A continuous quality improvement (CQI) program must include error tracking, root-cause analysis, corrective action, and follow-up monitoring.

Compounding must follow USP standards: USP <795> for nonsterile, <797> for sterile, and <800> for hazardous drugs, including facility, personnel, and environmental monitoring.

Sterile compounding requires validated processes, environmental monitoring, and documented training; deviations must be investigated and corrected.

Look-alike/sound-alike drugs, high-alert medications, and pediatric dosing require additional verification and independent double-checks.

Error reporting should be nonpunitive to encourage disclosure; the focus is system improvement rather than individual blame, while intentional misconduct remains subject to discipline.

Quality assurance records must be retained and available for inspection; the PIC is accountable for the CQI program and its documentation.

Patient safety events involving controlled substances also trigger inventory and theft/loss review in addition to the error review.

Grounds for discipline include practicing without a license, incompetence, unprofessional conduct, fraud or deception, impairment, and violation of drug laws or Board rules.

The Board may investigate complaints, subpoena records, and conduct hearings; the pharmacist is entitled to notice and an opportunity to respond.

Disciplinary actions may include reprimand, fine, probation, suspension, revocation, or restrictions on practice; the Board may also require remediation or monitoring.

Unprofessional conduct includes falsifying records, dispensing without a valid prescription, failing to counsel when required, and diverting drugs.

Due process requires notice of charges, a hearing, and the right to counsel; settlements may be reached through consent agreements.

A pharmacist must report certain conduct, including known diversion or impairment that poses a risk, and must cooperate with Board investigations.

Continuing education and competency requirements are conditions of licensure; failure to meet them can result in discipline or nonrenewal.

Discipline in another state or a federal action must be reported to the Minnesota Board; failure to report is itself a violation.

Minnesota licenses pharmacists, registers pharmacy technicians, and registers interns through the Board of Pharmacy; all three credentials must be current and in good standing before practicing in the state.

A Minnesota pharmacist license requires graduation from an ACPE-accredited program, passage of NAPLEX and MPJE, and a jurisprudence requirement; licensure by reciprocity/score transfer goes through the Board, not NABP alone.

Pharmacy technicians in Minnesota are registered (not licensed) by the Board; registration requires application, fee, and compliance with Board rules, and technician registration is distinct from national PTCB certification.

Pharmacy interns must be enrolled in an accredited pharmacy program and registered with the Board; intern registration permits supervised practice toward licensure and expires per Board rule.

A pharmacy must obtain a Board-issued pharmacy license for each location before dispensing; the license identifies the pharmacist-in-charge (PIC) and the licensed premises.

Out-of-state pharmacists generally may not practice into Minnesota on another state's license; nonresident pharmacies dispensing to Minnesota patients must register with the Minnesota Board as a nonresident pharmacy.

Credential renewals are time-limited; practicing on an expired license, registration, or pharmacy license is grounds for discipline even if renewal is later completed.

Change-of-address, name, employment, or PIC changes must be reported to the Board within the timeframe set by rule; failure to report is an independent violation.

Federal CSA places drugs in Schedules I–V; Schedule II has the strictest controls, no refills, and requires a written or qualifying electronic prescription except in defined emergencies.

Minnesota adopts the federal schedules by reference and adds state-specific controls; Minnesota Schedule I includes drugs with no accepted medical use and high abuse potential.

Minnesota's prescription monitoring program (PMP) requires dispensers to report controlled substance dispensations to the state database; pharmacists must check the PMP in specified circumstances before dispensing controlled substances.

Schedule II prescriptions may not be refilled; Schedule III–IV may be refilled up to five times within six months of issue; Schedule V refills follow state and label limits.

Controlled substance records (inventory, dispensing, invoices) must be kept per federal and state retention rules; Minnesota generally requires prescription records be retained for at least two years.

A DEA registration is required for each principal place of business where controlled substances are handled; state licensure is a prerequisite to DEA registration in Minnesota.

Theft or significant loss of controlled substances must be reported to DEA and to the Minnesota Board; the report is separate from routine inventory reconciliation.

Minnesota law restricts prescribing and dispensing of certain controlled substances and requires specific documentation for opioid prescriptions, including PDMP review and patient risk assessment.

A valid prescription requires the patient's name and address, drug name/strength/quantity, directions, prescriber's name and DEA number (for controlled substances), and date of issue.

Minnesota requires that prescriptions be dispensed as written unless substitution is permitted; generic substitution is allowed only when the prescriber has not prohibited it and the substituted product is therapeutically equivalent.

A pharmacist may not dispense on an expired prescription or one lacking required elements; the pharmacist must verify questionable prescriptions with the prescriber and document the contact.

Refills must be authorized by the prescriber and must not exceed the number stated or the legal maximum; Schedule II cannot be refilled.

Prescription transfers between pharmacies must be documented, include all required information, and are subject to limits for controlled substances under federal and state rules.

E-prescribing of controlled substances requires DEA-compliant software; paper prescriptions remain valid where allowed, but forgery indicators and prescriber verification are required.

Labels must include pharmacy name and address, prescription number, date, patient name, directions, drug name/strength, quantity, prescriber, and required auxiliary and cautionary statements.

Patient counseling must be offered on new prescriptions and when the pharmacist deems necessary; refusal must be documented, and counseling must be provided in a manner the patient understands.

Drugs must be stored under conditions that ensure stability; temperature, light, and humidity controls must be monitored and documented, and expired or adulterated stock must be quarantined.

Controlled substance inventory must be taken at registration and biennially thereafter; the inventory must be exact for Schedule II and estimated for III–V, and records retained.

Returns and reverse distribution must be documented; controlled substances may not be returned to stock after dispensing, and returned drugs must be handled under DEA and Board rules.

Drug recalls require identification of affected lots, quarantine, notification of patients when necessary, and documentation of the recall response.

Theft or loss of controlled substances must be reported to DEA (Form 106) and to the Minnesota Board; significant losses also require review of security controls.

Automated dispensing systems must maintain audit trails, restrict access, and be subject to the same recordkeeping and security standards as manual systems.

Records must be readily retrievable and retained for the required period; prescription and controlled substance records must be available for Board and DEA inspection.

Security requires limited access to the pharmacy, locked storage of controlled substances, and documented key/alarm control; the PIC is responsible for overall security.

Pharmacists may perform patient assessment, drug therapy review, and medication management; collaborative practice agreements allow defined therapy changes under protocol.

Minnesota pharmacists may administer immunizations to patients meeting age and protocol requirements; documentation and reporting to the state immunization registry are required.

Pharmacists may dispense naloxone under a standing order or protocol; no separate prescriber order is required when the state standing order is used.

Technicians may perform duties delegated by the supervising pharmacist, including preparation and dispensing tasks, but may not perform clinical assessment or final verification.

The pharmacist-in-charge is responsible for supervision, training, and ensuring technicians work within their registered scope; ratio and supervision rules must be followed.

Interns may perform pharmacist tasks under direct supervision of a licensed pharmacist; the supervising pharmacist remains responsible for the intern's actions.

A pharmacist may not delegate final verification of a prescription or clinical judgment to a technician; the pharmacist must review the completed prescription before dispensing.

Delegation must be documented and consistent with Board rules; a pharmacist who permits an unregistered or unsupervised person to perform restricted acts is subject to discipline.

Medication errors must be documented and reviewed; serious errors and sentinel events require internal review and may require reporting to the Board or other authorities.

A continuous quality improvement (CQI) program must include error tracking, root-cause analysis, corrective action, and follow-up monitoring.

Compounding must follow USP standards: USP <795> for nonsterile, <797> for sterile, and <800> for hazardous drugs, including facility, personnel, and environmental monitoring.

Sterile compounding requires validated processes, environmental monitoring, and documented training; deviations must be investigated and corrected.

Look-alike/sound-alike drugs, high-alert medications, and pediatric dosing require additional verification and independent double-checks.

Error reporting should be nonpunitive to encourage disclosure; the focus is system improvement rather than individual blame, while intentional misconduct remains subject to discipline.

Quality assurance records must be retained and available for inspection; the PIC is accountable for the CQI program and its documentation.

Patient safety events involving controlled substances also trigger inventory and theft/loss review in addition to the error review.

Grounds for discipline include practicing without a license, incompetence, unprofessional conduct, fraud or deception, impairment, and violation of drug laws or Board rules.

The Board may investigate complaints, subpoena records, and conduct hearings; the pharmacist is entitled to notice and an opportunity to respond.

Disciplinary actions may include reprimand, fine, probation, suspension, revocation, or restrictions on practice; the Board may also require remediation or monitoring.

Unprofessional conduct includes falsifying records, dispensing without a valid prescription, failing to counsel when required, and diverting drugs.

Due process requires notice of charges, a hearing, and the right to counsel; settlements may be reached through consent agreements.

A pharmacist must report certain conduct, including known diversion or impairment that poses a risk, and must cooperate with Board investigations.

Continuing education and competency requirements are conditions of licensure; failure to meet them can result in discipline or nonrenewal.

Discipline in another state or a federal action must be reported to the Minnesota Board; failure to report is itself a violation.